CoChat

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study

Open access
Bourin, Michel S, Severus, Emanuel, Schronen, Juan P, Gass, Peter, Szamosi, Johan, Eriksson, Hans, Chandrashekar, Hongally · 2014 · International Journal of Bipolar Disorders

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Quetiapine extended release (XR) and lithium are treatments with proven efficacy in acute mania. This randomized study evaluated the efficacy and safety of lithium or placebo as add-on to quetiapine XR in adult patients with manic or mixed symptoms of bipolar I disorder. In this 6-week, double-blind study (Trial D144AC00003), adult patients with DSM-IV-TR-diagnosed bipolar I disorder (current episode manic or mixed), a Young Mania Rating Scale (YMRS) total score ≥20, and score ≥4 on two of four core YMRS items were administered quetiapine XR (400 to 800 mg/day) and randomly assigned to receive add-on lithium (600 to 1,800 mg/day) or placebo. The primary efficacy end point was change in the YMRS total score from baseline to day 43, analyzed using a mixed-model for repeated measures (MMRM) approach. Secondary efficacy and safety end points were also measured. Rating scales were administered by trained staff. Three hundred fifty-six patients treated with quetiapine XR were randomized to add-on lithium (n = 173) or placebo (n = 183). Two hundred ninety-one patients (81.7%) completed the study. At day 43, least squares mean change in YMRS total score was -22.8 for add-on lithium and -20.1 for add-on placebo, a statistically significant treatment group difference of -2.69 (p < 0.001). On secondary measures, add-on lithium was associated with significant improvements in response, remission, illness severity, and overall illness versus add-on placebo (p < 0.05). The number needed to treat was 9.1 for response and 7.9 for remission for add-on lithium compared with add-on placebo. Lithium in combination with quetiapine XR was generally well tolerated, with a similar profile to quetiapine XR in combination with placebo. The addition of lithium to quetiapine XR therapy was associated with significantly greater efficacy than placebo as add-on and was generally well tolerated in patients with acute bipolar I mania. This study was registered under Clinicaltrials.gov Identifier NCT00931723.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40345-014-0014-9

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient disposition. a One randomized patient did not receive study treatment.
Figure 1 Patient disposition. a One randomized patient did not receive study treatment.CC BY · PubMed Central
Figure 2 Mean change in YMRS total score (with 95% CIs) from baseline (observed case data, ITT set).
Figure 2 Mean change in YMRS total score (with 95% CIs) from baseline (observed case data, ITT set).CC BY · PubMed Central
Figure 3 Mean changes in YMRS item scores from baseline (ITT set, MMRM analysis).
Figure 3 Mean changes in YMRS item scores from baseline (ITT set, MMRM analysis).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC; 2000.
  2. First MB, Williams JBW, Spitzer RL, Gibbon M: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). Biometrics Research, New York State Psychiatric Institute, New York; 2007.

Cited by

See all 40

Metadata

Authors
Bourin, M. S., Severus, E., Schronen, J. P., Gass, P., Szamosi, J., Eriksson, H., & Chandrashekar, H.
Affiliations
  • Université de Nantes (FR)
  • Technische Universität Dresden (DE)
  • Heidelberg University (DE)
  • AstraZeneca (Sweden) (SE)
Corresponding author
Bourin, Michel S
Venue
International Journal of Bipolar Disorders
Published
2014-11-08
Volume
2
Issue
1
Pages
14-14
ISSN
2194-7511 (ISSN-L)
OpenAlex
W2132972638
Cited by
40
References
49
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 3
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • International Journal of Bipolar Disorders (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
lithium, quetiapine extended release, acute mania, bipolar I disorder, adjunctive therapy, Young Mania Rating Scale, manic symptoms, mixed states, treatment response and remission, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. https://app.cochat.ai/papers/10.1186/s40345-014-0014-9
The paper
Bourin, M. S., Severus, E., Schronen, J. P., Gass, P., Szamosi, J., Eriksson, H., & Chandrashekar, H. (2014). Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. International Journal of Bipolar Disorders. https://doi.org/10.1186/s40345-014-0014-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.